Saturday 21 Jun, 2025 04:49 AM
Site map | Locate Us | Login
   Transformers and Rectifiers ends higher after bagging export order worth $16.65 million    Brahmaputra Infra edges higher after higher rental rates at Guwahati-based mall take effect    Astrazeneca Pharma India Ltd leads losers in 'A' group    Krishival Foods jumps 19% in four days    Sai Life Sciences rises on completion of second phase expansion at Bidar facility    Jaykay Enterprises Ltd leads losers in 'B' group    Volumes jump at Endurance Technologies Ltd counter    NTPC Green surges after India Ratings assigns 'AAA/A1+' rating to debt facilities with 'stable' outlook    Nestle India rises on bonus issue plan    Tamilnad Mercantile Bank trims lending rate by 50 bps; RLLR now at 8.50%    Mahindra & Mahindra Ltd spurts 2.69%, rises for third straight session    HDFC Bank Ltd spurts 1.08%, rises for third straight session    Sun TV slips on buzz of Maran family feud    AXISCADES Tech gains after inking MoU for defense systems production with Indra    Kakatiya Cement Sugar & Industries Ltd leads gainers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets
23-May-25   15:08 Hrs IST

Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood pressure (hypertension) and high cholesterol (hyperlipidemia).

The approved product is therapeutically equivalent to the reference listed drug, Caduet Tablets, marketed by Pharmacia and Upjohn Co. LLC.

The company now has a cumulative total of 223 ANDA approvals from the USFDA, including 199 final approvals and 24 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

The counter shed 0.13% to Rs 971.25 on the BSE.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 42098035
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited